Sweden’s RhoVac Aims To Become An M&A Target
Late 2021 RV001 Phase IIb Data May Offer Trigger, CEO Says
Executive Summary
RhoVac is in mid-stage trialing of a vaccine based on the RhoC protein that aids the metastatic potential of cancer cells and their ability to migrate and infiltrate other tissue. The Swedish biotech’s CEO believes the drug is a potential blockbuster.
You may also be interested in...
Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.